

## Company Overview

Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. These products are aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum's first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.

[Sign up here](#) to receive notices about press releases and SEC filings.

## Iterum Therapeutics Receives QIDP for Oral and IV Sulopenem in Four Additional Indications as well as Fast Track Designation

Mar 19 2019, 7:00 AM EDT

## Iterum to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference

Feb 19 2019, 7:30 AM EST

## Iterum Reports Third Quarter 2018 Financial Results and Recent Highlights

Nov 14 2018, 7:15 AM EST

## Stock Overview

Symbol	ITRM
Exchange	Nasdaq
Market Cap	102.94m
Last Price	\$7.27
52-Week	\$4.70 - \$13.00

03/22/2019 04:00 PM EDT

## Investor Relations

[ir@iterumtx.com](mailto:ir@iterumtx.com)

## Management Team

### Corey N. Fishman

Chief Executive Officer

### Michael Dunne, MD

Chief Scientific Officer

### Judith M. Matthews

Chief Financial Officer

### Benjamin M. Pe

Vice President Operations

### John J. White

Vice President Business Development & Supply Chain

### Tom Loughman, PhD

Vice President and CMC Head

## Iterum Therapeutics plc

200 S Wacker Drive  
Suite 2550  
Chicago, IL 60606  
USA

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.